[go: up one dir, main page]

HUE050400T2 - Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer - Google Patents

Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer

Info

Publication number
HUE050400T2
HUE050400T2 HUE15743367A HUE15743367A HUE050400T2 HU E050400 T2 HUE050400 T2 HU E050400T2 HU E15743367 A HUE15743367 A HU E15743367A HU E15743367 A HUE15743367 A HU E15743367A HU E050400 T2 HUE050400 T2 HU E050400T2
Authority
HU
Hungary
Prior art keywords
enhances
injury
salt
agent
alkyl ether
Prior art date
Application number
HUE15743367A
Other languages
English (en)
Inventor
Takuya Takahashi
Tomohiro Okuda
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of HUE050400T2 publication Critical patent/HUE050400T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE15743367A 2014-01-31 2015-01-30 Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer HUE050400T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014017587 2014-01-31

Publications (1)

Publication Number Publication Date
HUE050400T2 true HUE050400T2 (hu) 2020-12-28

Family

ID=53757150

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15743367A HUE050400T2 (hu) 2014-01-31 2015-01-30 Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer

Country Status (26)

Country Link
US (2) US10039744B2 (hu)
EP (1) EP3100725B1 (hu)
JP (3) JP5837726B1 (hu)
KR (1) KR102346219B1 (hu)
CN (1) CN106061478B (hu)
AU (1) AU2015211753B2 (hu)
BR (1) BR112016017747A2 (hu)
CA (1) CA2938184C (hu)
CY (1) CY1123154T1 (hu)
DK (1) DK3100725T3 (hu)
ES (1) ES2792950T3 (hu)
HR (1) HRP20200796T1 (hu)
HU (1) HUE050400T2 (hu)
IL (1) IL246925B (hu)
LT (1) LT3100725T (hu)
MX (1) MX2016009751A (hu)
MY (1) MY179290A (hu)
PH (1) PH12016501507A1 (hu)
PL (1) PL3100725T3 (hu)
PT (1) PT3100725T (hu)
RS (1) RS60462B1 (hu)
RU (1) RU2680247C2 (hu)
SG (2) SG10201907035TA (hu)
SI (1) SI3100725T1 (hu)
SM (1) SMT202000395T1 (hu)
WO (1) WO2015115582A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050400T2 (hu) * 2014-01-31 2020-12-28 Fujifilm Toyama Chemical Co Ltd Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer
CA3009152C (en) * 2015-12-25 2023-08-15 Toyama Chemical Co., Ltd. Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
CN110167552B (zh) * 2016-12-28 2023-05-02 富士胶片富山化学株式会社 医药组合物及其制造方法
EP3563847B1 (en) * 2016-12-28 2023-09-20 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
WO2018124281A1 (ja) * 2016-12-28 2018-07-05 富山化学工業株式会社 外用組成物
JP7057286B2 (ja) 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
US11660287B2 (en) * 2017-06-02 2023-05-30 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
CA3067458C (en) 2017-06-02 2022-11-01 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid .beta. protein
NZ759657A (en) * 2017-06-02 2022-07-29 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating tauopathy
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
US11951092B2 (en) 2017-06-02 2024-04-09 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating brain atrophy
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230407B1 (hu) 2001-10-19 2016-04-28 Toyama Chemical Co., Ltd. Alkil-éter-származékok és sóik
WO2003045137A1 (fr) 2001-11-29 2003-06-05 Japan Science And Technology Agency Procede de construction d'un modele simien de lesion spinale et son utilisation
BRPI0311780B8 (pt) 2002-06-14 2021-05-25 Toyama Chemical Co Ltd composição farmacêutica para melhorar a função cerebral
NZ543100A (en) * 2003-04-17 2008-07-31 Toyama Chemical Co Ltd Preventive/remedy for retinal nerve dieases containing alkyl ether derivatives or salts thereof
EP1864978A4 (en) 2005-03-28 2009-07-01 Toyama Chemical Co Ltd PROCESS FOR PREPARING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) ETHOXY) PROPYL) AZETIDIN-3-OL OR SALTS THEREOF
RU2397169C2 (ru) * 2005-03-28 2010-08-20 Тояма Кемикал Ко., Лтд. Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US20090093453A1 (en) * 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
HUE050400T2 (hu) * 2014-01-31 2020-12-28 Fujifilm Toyama Chemical Co Ltd Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer

Also Published As

Publication number Publication date
EP3100725B1 (en) 2020-05-06
SG11201606173TA (en) 2016-08-30
MY179290A (en) 2020-11-03
AU2015211753B2 (en) 2019-09-12
CA2938184A1 (en) 2015-08-06
PL3100725T3 (pl) 2020-11-16
SI3100725T1 (sl) 2020-08-31
AU2015211753A1 (en) 2016-08-11
PT3100725T (pt) 2020-06-17
JP6825074B2 (ja) 2021-02-03
EP3100725A4 (en) 2017-08-30
JPWO2015115582A1 (ja) 2017-03-23
RU2680247C2 (ru) 2019-02-19
EP3100725A1 (en) 2016-12-07
JP2020073542A (ja) 2020-05-14
JP5837726B1 (ja) 2015-12-24
WO2015115582A1 (ja) 2015-08-06
HK1226298A1 (en) 2017-09-29
DK3100725T3 (da) 2020-06-22
JP2016074676A (ja) 2016-05-12
HRP20200796T1 (hr) 2020-08-07
US10039744B2 (en) 2018-08-07
LT3100725T (lt) 2020-08-10
US20170165227A1 (en) 2017-06-15
CA2938184C (en) 2021-11-23
PH12016501507A1 (en) 2017-02-06
KR102346219B1 (ko) 2022-01-04
NZ722542A (en) 2021-07-30
IL246925B (en) 2019-10-31
MX2016009751A (es) 2016-11-08
BR112016017747A2 (pt) 2017-08-08
CN106061478B (zh) 2019-04-30
IL246925A0 (en) 2016-09-29
KR20160113281A (ko) 2016-09-28
RS60462B1 (sr) 2020-07-31
CY1123154T1 (el) 2021-10-29
CN106061478A (zh) 2016-10-26
JP6642914B2 (ja) 2020-02-12
SG10201907035TA (en) 2019-09-27
US10471044B2 (en) 2019-11-12
ES2792950T3 (es) 2020-11-12
US20180289668A1 (en) 2018-10-11
RU2016135236A3 (hu) 2018-08-30
SMT202000395T1 (it) 2020-09-10
RU2016135236A (ru) 2018-03-02

Similar Documents

Publication Publication Date Title
NO2025025I1 (no) Lazertinib in all its forms protected by the basic patent
HUE050400T2 (hu) Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer
LT3240415T (lt) Fungicidinės kompozicijos
DK3233221T3 (da) Træningsindretning
DK3613447T3 (da) Humane pancreas-scaffolds
BR112017001922A2 (pt) composições fungicidas
PL3166680T3 (pl) Profilaktyka przedekspozycyjna anty-hsv
HRP20190336T1 (hr) Derivati 6-alkinilpiridina kao smac-mimetici
LT3119410T (lt) Raminamasis feromonas katėms
DK3035303T3 (da) Returautomat
DK2901861T3 (da) Flåmaskine
LT3270923T (lt) Terapinis agentas priekinės skilties disfunkcijai
ES1109056Y (es) Cama abatible
UA30734S (uk) Опаковання для мюслі «start!»
TH1501007638A (th) สารรักษาความชุ่มชื้น
HRP20181460T1 (hr) Derivati 4-okso-n-(4-hidroksifenil)retinamida kao terapeutska sredstva za liječenje karcinoma
ES1133683Y (es) Calcetin para prevenir lesiones
DK3171141T3 (da) Kombinationsvægtindretning
UA29759S (uk) Оболонка для ковбас «магрок»
UA30649S (uk) Сосиска «тигрик»
UA30537S (uk) Іграшка «комунальна машина»
DK2984925T3 (da) Løbeboks
TH1601001122B (th) ผลิตภัณฑ์ดูดซึม
TH1601002523B (th) วิธีการสร้างวัตถุ
ES1135522Y (es) Delantal perfeccionado